James Paton

Stay informed with James Paton’s coverage and analysis for Fortune.

Page 2 of 3

WASHINGTON, DC – DECEMBER 08: Ivanka Trump, senior advisor to her father U.S. President Donald Trump listens at the Operation Warp Speed Vaccine Summit on December 08, 2020 in Washington, DC. The president signed an executive order stating the US would provide vaccines to Americans before aiding other nations. (Photo by Tasos Katopodis/Getty Images)

How vaccine nationalism could extend the pandemic

By James Paton and Bloomberg

SAO PAULO, BRAZIL – JANUARY 17: A nurse administers a dose of the CoronaVac vaccine to a medical worker at Hospital das Clinicas of the University of Sao Paulo (USP) on January 17, 2021 in Sao Paulo, Brazil. The CoronaVac vaccine was developed by the Chinese laboratory Sinovac in partnership with the Butantan Institute. The National Health Surveillance Agency (Anvisa) authorized today the emergency use of the CoronaVac and the AstraZeneca (developed by the University of Oxford in partnership with the Oswaldo Cruz Foundation (Fiocruz) vaccines against Covid-19. (Photo by Rodrigo Paiva/Getty Images)

Public health officials warn about slow vaccine rollout as coronavirus variants multiply

By James Paton and Bloomberg

STEVENAGE, ENGLAND – JANUARY 11: Sylvia Staff 83, receives an injection of a Covid-19 vaccine at the NHS vaccine centre that has been set up at Robertson House on January 11, 2021 in Stevenage, England. The location is one of several mass vaccination centres in England to open to the public this week. The UK aims to vaccinate 15 million people by mid-February. (Photo by Joe Giddens – WPA Pool/Getty Images)

Drugmakers hit back at U.K. plan to delay the second dose of COVID vaccines

By James Paton and Bloomberg

Shares in AstraZeneca were down 1% after the drugmaker disclosed it was pausing its COVID-19 vaccine trial. Initially, that sent markets lower, before recovering.

AstraZeneca acquires rare-disease specialist Alexion in $39 billion deal

By John Lauerman, James Paton, and others

Nurses at the Royal Free Hospital, London, simulate the administration of the Pfizer vaccine to support staff training ahead of the rollout, which begins tomorrow. Wire photography: Yui Mok – WPA Pool—Getty Images

Britons will roll up their sleeves on Tuesday for a COVID vaccine jab as the world anxiously watches

By James Paton, Suzi Ring, and others

Pfizer is developing the Covid-19 vaccine 95% effective and safe

U.K. approves Pfizer COVID-19 vaccine and will start distributing it next week

By James Paton and Bloomberg

AstraZeneca eyes another global trial for its COVID vaccine following dosage blip

By Suzi Ring, James Paton, and others

A laboratory technician supervises capped vials during filling and packaging tests for the large-scale production and supply of the University of Oxfords COVID-19 vaccine candidate, AZD1222, conducted on a high-performance aseptic vial filling line on September 11, 2020 at the Italian biologics manufacturing facility of multinational corporation Catalent in Anagni, southeast of Rome, during the COVID-19 infection, caused by the novel coronavirus. – Catalent Biologics manufacturing facility in Anagni, Italy will serve as the launch facility for the large-scale production and supply of the University of Oxfords Covid-19 vaccine candidate, AZD1222, providing large-scale vial filling and packaging to British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca. (Photo by Vincenzo PINTO / AFP) (Photo by VINCENZO PINTO/AFP via Getty Images)

Oxford says COVID-19 vaccine has produced strong immune response ahead of late-stage trial results

By James Paton, Suzi Ring, and others

Researchers continue to puzzle over why the COVID vaccine developed by AstraZeneca and Oxford University appears to be more effective on a half dose. Wire photography: Lisa Maree Williams—Getty Images

AstraZeneca-Oxford COVID vaccine on track for year end, CEO Pascal Soriot says

By Suzi Ring, James Paton, and others

The U.K. is considering so-called “challenge trials” to speed up COVID-19 vaccine development.

To jumpstart the COVID vaccine race, the U.K. considers ‘challenge trials’ exposing people to the virus

By James Paton and Bloomberg

Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, poses for a photograph at the company’s headquarter offices in Copenhagen, Denmark on Aug. 31, 2018.

Weight loss and obesity drugs could help fight COVID-19, Novo Nordisk says

By James Paton and Bloomberg

A researcher wearing a face mask and gloves as a preventive

These countries aren’t waiting for a U.S., China, or U.K. COVID vaccine

By James Paton and Bloomberg

Vaccines in prefilled, single-use syringes before the inspection and packaging phase at the French pharmaceutical company Sanofi’s world distribution centre in Val de Reuil on July 10, 2020.

U.S. pledges $2.1 billion for up to 600 million doses of Sanofi, GlaxoSmithKline vaccine

By James Paton and Bloomberg

CHINA-HEALTH-VIRUS

The earliest coronavirus vaccines may not protect you from getting infected

By John Lauerman, James Paton, and others

Paul Hudson, chief executive officer of Sanofi, is close to selling a stake in high-flying Regeneron Pharmaceuticals, a deal that could net the French pharma giant $13 billion.

France’s Sanofi to sell stake in high-flying Regeneron to fund new drugs discoveries

By James Paton, Riley Griffin, and others